Numerous studies have uncovered that FGF21 causes considerable pharmacological benefits on metabolic diseases, such as hyperglycemia, insulin resistance, dyslipidemia, and other obesity-related disorders27. The gene discussed is FGF21; the disease is metabolic syndrome.